Cargando…

Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer

BACKGROUND: We investigated the expression of two α(v) integrins, α(v)β(3) and α(v)β(5), in gastric cancer (GC) by testing the following hypotheses: that these molecules are expressed in GC; that they are implicated in GC biology; that they help to distinguish between the two major histological subt...

Descripción completa

Detalles Bibliográficos
Autores principales: Böger, Christine, Warneke, Viktoria S., Behrens, Hans-Michael, Kalthoff, Holger, Goodman, Simon L., Becker, Thomas, Röcken, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572058/
https://www.ncbi.nlm.nih.gov/pubmed/25315085
http://dx.doi.org/10.1007/s10120-014-0435-2
_version_ 1782390386095816704
author Böger, Christine
Warneke, Viktoria S.
Behrens, Hans-Michael
Kalthoff, Holger
Goodman, Simon L.
Becker, Thomas
Röcken, Christoph
author_facet Böger, Christine
Warneke, Viktoria S.
Behrens, Hans-Michael
Kalthoff, Holger
Goodman, Simon L.
Becker, Thomas
Röcken, Christoph
author_sort Böger, Christine
collection PubMed
description BACKGROUND: We investigated the expression of two α(v) integrins, α(v)β(3) and α(v)β(5), in gastric cancer (GC) by testing the following hypotheses: that these molecules are expressed in GC; that they are implicated in GC biology; that they help to distinguish between the two major histological subtypes of GC, according to Laurén; and that they are prognostically relevant. METHODS: Formalin-fixed and paraffin-embedded tissue samples from 482 GC samples were stained immunohistochemically using rabbit monoclonal antibodies directed against α(v)β(3) (EM22703) and α(v)β(5) (EM09902). Immunostaining of tumor, stroma, and endothelial cells was evaluated separately by the quantity and intensity, generating an immunoreactivity score. The immunoreactivity score of both antibodies was correlated with clinicopathology data and patient survival. RESULTS: Each integrin was expressed in at least one tumor component in all GCs. Both were expressed significantly more often in the intestinal phenotype according to Laurén. Moreover, patients who grouped as “positive” for expression of α(v)β(3) on endothelial cells, and patients with an intestinal type GC, grouped as “negative” for expression of α(v)β(5) on stroma cells, had significantly longer survival. The expression of α(v)β(5) on stroma cells was confirmed to be an independent prognostic factor of intestinal-type GC. CONCLUSION: The expression of α(v)β(3) and α(v)β(5) in at least one tumor component in all GC samples is an interesting new result that should form a basis for further investigations; for example, regarding selective integrin antagonists and the value of α(v)β(3) and α(v)β(5) as putative prognostic biomarkers. Moreover, both markers might be helpful in the routine classification of GC subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10120-014-0435-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4572058
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-45720582015-09-23 Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer Böger, Christine Warneke, Viktoria S. Behrens, Hans-Michael Kalthoff, Holger Goodman, Simon L. Becker, Thomas Röcken, Christoph Gastric Cancer Original Article BACKGROUND: We investigated the expression of two α(v) integrins, α(v)β(3) and α(v)β(5), in gastric cancer (GC) by testing the following hypotheses: that these molecules are expressed in GC; that they are implicated in GC biology; that they help to distinguish between the two major histological subtypes of GC, according to Laurén; and that they are prognostically relevant. METHODS: Formalin-fixed and paraffin-embedded tissue samples from 482 GC samples were stained immunohistochemically using rabbit monoclonal antibodies directed against α(v)β(3) (EM22703) and α(v)β(5) (EM09902). Immunostaining of tumor, stroma, and endothelial cells was evaluated separately by the quantity and intensity, generating an immunoreactivity score. The immunoreactivity score of both antibodies was correlated with clinicopathology data and patient survival. RESULTS: Each integrin was expressed in at least one tumor component in all GCs. Both were expressed significantly more often in the intestinal phenotype according to Laurén. Moreover, patients who grouped as “positive” for expression of α(v)β(3) on endothelial cells, and patients with an intestinal type GC, grouped as “negative” for expression of α(v)β(5) on stroma cells, had significantly longer survival. The expression of α(v)β(5) on stroma cells was confirmed to be an independent prognostic factor of intestinal-type GC. CONCLUSION: The expression of α(v)β(3) and α(v)β(5) in at least one tumor component in all GC samples is an interesting new result that should form a basis for further investigations; for example, regarding selective integrin antagonists and the value of α(v)β(3) and α(v)β(5) as putative prognostic biomarkers. Moreover, both markers might be helpful in the routine classification of GC subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10120-014-0435-2) contains supplementary material, which is available to authorized users. Springer Japan 2014-10-15 2015 /pmc/articles/PMC4572058/ /pubmed/25315085 http://dx.doi.org/10.1007/s10120-014-0435-2 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Böger, Christine
Warneke, Viktoria S.
Behrens, Hans-Michael
Kalthoff, Holger
Goodman, Simon L.
Becker, Thomas
Röcken, Christoph
Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer
title Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer
title_full Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer
title_fullStr Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer
title_full_unstemmed Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer
title_short Integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer
title_sort integrins α(v)β(3) and α(v)β(5) as prognostic, diagnostic, and therapeutic targets in gastric cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572058/
https://www.ncbi.nlm.nih.gov/pubmed/25315085
http://dx.doi.org/10.1007/s10120-014-0435-2
work_keys_str_mv AT bogerchristine integrinsavb3andavb5asprognosticdiagnosticandtherapeutictargetsingastriccancer
AT warnekeviktorias integrinsavb3andavb5asprognosticdiagnosticandtherapeutictargetsingastriccancer
AT behrenshansmichael integrinsavb3andavb5asprognosticdiagnosticandtherapeutictargetsingastriccancer
AT kalthoffholger integrinsavb3andavb5asprognosticdiagnosticandtherapeutictargetsingastriccancer
AT goodmansimonl integrinsavb3andavb5asprognosticdiagnosticandtherapeutictargetsingastriccancer
AT beckerthomas integrinsavb3andavb5asprognosticdiagnosticandtherapeutictargetsingastriccancer
AT rockenchristoph integrinsavb3andavb5asprognosticdiagnosticandtherapeutictargetsingastriccancer